Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Dec 9

PMID 34880877

Citations 6

Authors

Yanghui Ye

Song Zheng

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic cancer has a poor prognosis, and it is traditionally treated with chemotherapy. Fortunately, immunotherapy has rapidly changed the landscape of solid tumor treatment, and improving the survival of cancer patients. However, pancreatic cancer is non-immunogenic, and single agent immunotherapies are unfavorable to its prognosis.

Case Presentation: Here, we report a case of stage IV pancreatic cancer in a patient with TSC2 and SMAD4 mutations treated with immunotherapy when the disease progressed after multi-line chemotherapy. Next generation sequencing (NGS) confirmed the presence of TSC2 and SMAD4 mutations and microsatellite stability (MSS). When the disease progressed after chemotherapy, a combination strategy was devised consisting of chemotherapy (S-1) and sintilimab. The patient had a partial response to therapy with this regimen, the lesions were significantly reduced and nearly disappeared. In metastatic pancreatic cancer, responses of this magnitude are rarely seen.

Conclusions: This outcome reveals that this combination can be effective in treating metastatic pancreatic cancer, especially in pancreatic cancer patients with SMAD4 and TSC2 mutations. This may help increase the use of this therapy in large-scale clinical research.

Citing Articles

Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma.

Zhou S, Wan P, Zhang S, Ren Y, Li H, Ke Q World J Clin Oncol. 2025; 16(2):98079.

PMID: 39995563 PMC: 11686555. DOI: 10.5306/wjco.v16.i2.98079.

First reported advanced pancreatic cancer with hyperprogression treated with PD-1 blockade combined with chemotherapy: a case report and literature review.

Wang Y, Peng M, Xu Y, Ying Y, Tang L, Xu H Discov Oncol. 2024; 15(1):560.

PMID: 39404967 PMC: 11480291. DOI: 10.1007/s12672-024-01420-3.

The Current Landscape of Clinical Trials for Immunotherapy in Pancreatic Cancer: A State-of-the-Art Review.

Sarfraz Z, Sarfraz A, Farooq M, Khalid M, Cheema K, Javad F J Gastrointest Cancer. 2024; 55(3):1026-1057.

PMID: 38976079 DOI: 10.1007/s12029-024-01078-8.

Nimbolide: A Potential Phytochemical Agent in Multimodal Pancreatic Cancer Therapies.

Jogi M, Asnani H, Singh S, Kumar P Mini Rev Med Chem. 2024; 25(1):27-41.

PMID: 38874049 DOI: 10.2174/0113895575293138240527061556.

Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden.

Dai M, Sheng J, Zhang Q, Wang J, Fu Q, Liang T Front Oncol. 2023; 13:1118633.

PMID: 36937383 PMC: 10016350. DOI: 10.3389/fonc.2023.1118633.

References

OReilly E, Oh D, Dhani N, Renouf D, Lee M, Sun W . Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019; 5(10):1431-1438. PMC: 6647002. DOI: 10.1001/jamaoncol.2019.1588. View

Chen M, Yang S, Fan L, Wu L, Chen R, Chang J . Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report. Pancreas. 2019; 48(9):1232-1236. PMC: 6830947. DOI: 10.1097/MPA.0000000000001398. View

Biankin A, Morey A, Lee C, Kench J, Biankin S, Hook H . DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol. 2002; 20(23):4531-42. DOI: 10.1200/JCO.2002.12.063. View

Zitvogel L, Galluzzi L, Smyth M, Kroemer G . Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013; 39(1):74-88. DOI: 10.1016/j.immuni.2013.06.014. View

Duda D, Sunamura M, Lefter L, Furukawa T, Yokoyama T, Yatsuoka T . Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene. 2003; 22(44):6857-64. DOI: 10.1038/sj.onc.1206751. View

Tauriello D, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M . TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018; 554(7693):538-543. DOI: 10.1038/nature25492. View

Wainberg Z, Hochster H, Kim E, George B, Kaylan A, Chiorean E . Open-label, Phase I Study of Nivolumab Combined with -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clin Cancer Res. 2020; 26(18):4814-4822. DOI: 10.1158/1078-0432.CCR-20-0099. View

Larson C, Oronsky B, Carter C, Oronsky A, Knox S, Sher D . TGF-beta: a master immune regulator. Expert Opin Ther Targets. 2020; 24(5):427-438. DOI: 10.1080/14728222.2020.1744568. View

Royal R, Levy C, Turner K, Mathur A, Hughes M, Kammula U . Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010; 33(8):828-33. PMC: 7322622. DOI: 10.1097/CJI.0b013e3181eec14c. View

10.

Cingarlini S, Bonomi M, Corbo V, Scarpa A, Tortora G . Profiling mTOR pathway in neuroendocrine tumors. Target Oncol. 2012; 7(3):183-8. DOI: 10.1007/s11523-012-0226-9. View

11.

Dang H, White B, Foltz S, Miller C, Luo J, Fields R . ClonEvol: clonal ordering and visualization in cancer sequencing. Ann Oncol. 2017; 28(12):3076-3082. PMC: 5834020. DOI: 10.1093/annonc/mdx517. View

12.

Neesse A, Algul H, Tuveson D, Gress T . Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015; 64(9):1476-84. DOI: 10.1136/gutjnl-2015-309304. View

13.

Wang Y, Chu J, Yi P, Dong W, Saultz J, Wang Y . SMAD4 promotes TGF-β-independent NK cell homeostasis and maturation and antitumor immunity. J Clin Invest. 2018; 128(11):5123-5136. PMC: 6205382. DOI: 10.1172/JCI121227. View

14.

OHara M, OReilly E, Varadhachary G, Wolff R, Wainberg Z, Ko A . CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021; 22(1):118-131. DOI: 10.1016/S1470-2045(20)30532-5. View

15.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

16.

Wagner M, Kleeff J, Lopez M, Bockman I, Massaque J, Korc M . Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. Int J Cancer. 1998; 78(2):255-60. DOI: 10.1002/(sici)1097-0215(19981005)78:2<255::aid-ijc21>3.0.co;2-8. View

17.

Yamada S, Fujii T, Shimoyama Y, Kanda M, Nakayama G, Sugimoto H . SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer. Pancreas. 2015; 44(4):660-4. DOI: 10.1097/MPA.0000000000000315. View

18.

Bockorny B, Macarulla T, Semenisty V, Borazanci E, Feliu J, Ponz-Sarvise M . Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. Clin Cancer Res. 2021; 27(18):5020-5027. DOI: 10.1158/1078-0432.CCR-21-0929. View

19.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

20.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View